$0.53 $0.01 (0.0%)

03:04 PM EDT on 06/14/19

Intelgenx Technologies Corp (NASDAQOTH:IGXT)

CAPS Rating: No stars

Current Price $0.53 Mkt Cap $65.5M
Open $0.51 P/E Ratio 0.00
Prev. Close $0.53 Div. (Yield) $0.00 (0.0%)
Daily Range $0.50 - $0.53 Volume 28,849
52-Wk Range $0.43 - $0.80 Avg. Daily Vol.

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

18 Outperform
8 Underperform
 

All-Star Players

4 Outperform
6 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQOTH:IGXT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Stockhero (< 20)
Submitted November 16, 2011

Strong fundamentals here.. One of the cheapest Biotech Stock out there !1)Very Very low Market cap of $23.5 M2) Mega drug Pipeline of 9 Products including a potential Blockbuster3) 2 New NDA filing in 20124) NO DEBT5)Cash till 20146) Very strong… More

zzlangerhans (99.82)
Submitted July 13, 2013

I haven't had much success figuring out how IntelGenX keeps cash in their accounts despite not making any money on their one approved drug Forfivo XL and doing very little in the way of financing. They only use 0.5M a quarter on operations despite… More

NASDAQOTH:IGXT VS S&P 500 (SPY)

NASDAQOTH:IGXT Summary

Fools bullish on NASDAQOTH:IGXT are also bullish on:

Fools bearish on NASDAQOTH:IGXT are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about IGXT.

Recs

0
Member Avatar someboy0808 (< 20) Submitted: 8/26/2013 3:07:42 PM : Outperform Start Price: $0.50 NASDAQ OTHER:IGXT Score: -68.19

Optimist on going above 1 dollar within 1-2 year

Recs

3
Member Avatar Stockhero (< 20) Submitted: 11/16/2011 1:53:20 AM : Outperform Start Price: $0.57 NASDAQ OTHER:IGXT Score: -139.30

Strong fundamentals here.. One of the cheapest Biotech Stock out there !

1)Very Very low Market cap of $23.5 M
2) Mega drug Pipeline of 9 Products including a potential Blockbuster
3) 2 New NDA filing in 2012
4) NO DEBT
5)Cash till 2014
6) Very strong Institutions and Insider in this stock
7) low float Stock

Intelgenx (IGXT.OB)

Market Cap : $26.1 M
Price: 0.56

IntelGenx Announces FDA Approval of Its High Dose Anti-Depressant CPI-300
http://finance.yahoo.com/news/IntelGenx-Announces-FDA-pz-4172746127.html?x=0&l=1

Company Presentation
http://www.intelgenx.com/_assets/pdf/Intelgenx-Presentation.pdf

Ownership
http://data.cnbc.com/quotes/IGXT.OB/tab/8

interview with ceo
zerbe
http://www.cantechletter.com/2010/12/cantech-letter-interviews-horst-zerbe-president-and-ceo-of-intelgenx/

Article
http://www.biomedreports.com/2011111183312/fda-spproval-is-a-game-changer-for-intelgen

Leaderboard

Find the members with the highest scoring picks in IGXT.

Score Leader

zzlangerhans

zzlangerhans (99.82) Score: +160.52

The question to be answered soon is whether health insurance will pay for a medication to be given in one tablet to save someone the bother of taking two tablets of a cheap generic.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
IdahoInvestor 35.04 6/3/2013 Underperform 5Y $0.55 -3.67% +77.51% +81.18 0 Comment
JoeySolitro1 99.99 9/6/2016 Underperform 5Y $0.93 -43.03% +32.58% +75.62 0 Comment
Toprope101 99.90 9/6/2016 Underperform 5Y $0.91 -41.78% +32.55% +74.33 0 Comment
Doppelganger 32.55 9/13/2016 Underperform 5Y $0.75 -29.54% +35.89% +65.42 0 Comment
JoeySolitro3 98.63 9/29/2016 Underperform 5Y $0.77 -31.19% +33.70% +64.90 0 Comment
RayNobleEsq 99.98 2/15/2019 Underperform 5Y $0.68 -21.97% +4.89% +26.86 0 Comment
anchak 99.92 2/15/2019 Underperform 5Y $0.68 -21.97% +4.89% +26.86 0 Comment
liszewski 99.95 11/12/2018 Underperform 5Y $0.60 -11.70% +4.57% +16.27 0 Comment
Shepp67 33.51 1/3/2014 Outperform 1Y $0.57 -7.05% +58.54% -65.59 0 Comment
gmc2500hd < 20 1/10/2017 Outperform 3Y $0.89 -40.47% +27.72% -68.19 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for IGXT.

Advertisement